Effects of Fat-soluble Vitamins Supplementation on Common Complications and Neural Development in Very Low Birth Weight Infants
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03876704 |
Recruitment Status :
Recruiting
First Posted : March 15, 2019
Last Update Posted : March 15, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Vitamin A Deficiency Vitamin D Deficiency Vitamin E Deficiency Very Low Birth Weight Infants Bronchopulmonary Dysplasia Anemia Sepsis | Drug: High dose of fat-Soluble Vitamin Drug: Conventional dose of fat-Soluble Vitamin | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants |
Actual Study Start Date : | January 29, 2019 |
Estimated Primary Completion Date : | September 30, 2019 |
Estimated Study Completion Date : | December 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: High dose of fat-soluble vitamins
Fat-soluble vitamins is administered 0.5 piece/kg (equals to 1150 U/kg vitamin A,200 U/kg vitamin D, 3.2 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
|
Drug: High dose of fat-Soluble Vitamin
Supplementation of 5 times current dose of fat-soluble vitamins by intravenous perfusion |
Active Comparator: Conventional dose of fat-soluble vitamins
Fat-soluble vitamins is administered 0.1 piece/kg (equals to 230 U/kg vitamin A,40 U/kg vitamin D, 0.64 U/kg vitamin E) intravenously every day until the baby achieve full enteral feeding (120 ml/kg), starting with the first dose within 24 hours after birth.
|
Drug: Conventional dose of fat-Soluble Vitamin
Supplementation of the current dose of fat-soluble vitamins by intravenous perfusion |
- Vitamin levels [ Time Frame: within 72 hours after birth, 4~6 weeks old ]Change from baseline level of vitamin A, vitamin D, and vitamin E at 4~6 weeks
- Complications [ Time Frame: corrected age of 36 weeks ]The prevalence of bronchopulmonary dysplasia, patent ductus arteriosus, sepsis, anemia, intracranial hemorrhage, extrauterine growth retardation, etc.
- Neural development [ Time Frame: corrected age of 40 weeks ]White matter disease of the preterm infant, was semiquantitatively assessed from MRI at term-equivalent age based on an established scoring method.
- Gene polymorphism in vitamin deficiency preterm infants [ Time Frame: within 72 hours after birth, 4~6 weeks old ]Association of rs4588 polymorphism in vitamin D receptor gene and rs10766197 polymorphism in the cytochrome P450 family 2 subfamily R member 1 gene with baseline level of vitamin D and change in vitamin D level after 4~6 weeks' supplementation

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | up to 24 Hours (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- admitted to the neonatal intensive care unit (NICU) within 24 hours after birth
- gestational age younger than 34 weeks
- birth weight less than 1500 gram
- informed consent was obtained from the infants' parents or guardians
Exclusion Criteria:
- congenital malformation
- chromosomal disease, genetic metabolic diseases
- the infants or his/mother has abnormal thyroid function or parathyroid gland function
- neonatal necrotizing enterocolitis, diarrhea
- intracranial hemorrhage of 3 degrees or above
- pulmonary hemorrhage
- liver enzymes elevated by more than 2 times, cholestasis
- death or discharge against medical advice
- refuse to take part in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03876704
Contact: Shuang Liu | 008615201524806 | liushuangpku@126.com |
China, Shaanxi | |
First Affiliated Hospital of Xian JiaotongUniversity | Recruiting |
Xi'an, Shaanxi, China, 710061 | |
Contact: Xihui Zhou |
Study Director: | Shuang Liu | First Affiliated Hospital of Xian JiaotongUniversity |
Other Publications:
Responsible Party: | First Affiliated Hospital Xi'an Jiaotong University |
ClinicalTrials.gov Identifier: | NCT03876704 |
Other Study ID Numbers: |
2018MSZC-04 |
First Posted: | March 15, 2019 Key Record Dates |
Last Update Posted: | March 15, 2019 |
Last Verified: | February 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Bronchopulmonary Dysplasia Night Blindness Vitamin D Deficiency Vitamin A Deficiency Vitamin E Deficiency Body Weight Birth Weight Avitaminosis Deficiency Diseases Malnutrition Nutrition Disorders Ventilator-Induced Lung Injury |
Lung Injury Lung Diseases Respiratory Tract Diseases Infant, Premature, Diseases Infant, Newborn, Diseases Vision Disorders Eye Diseases Vitamins Micronutrients Nutrients Growth Substances Physiological Effects of Drugs |